Showing 7011-7020 of 8649 results for "".
- University of Cincinnati Study Finds Fear of Vision Loss is a Barrier to Cataract Surgeryhttps://modernod.com/news/university-of-cincinnati-study-finds-fear-of-vision-loss-is-a-barrier-to-cataract-surgery/2482761/Fear of vision loss, particularly among patients who have a visually significant cataract in only one eye, may deter some from undergoing cataract surgery, according to a new study from the Department of Ophthalmology at the University of Cincinnati (UC). The study,
- Brent Saunders: Bausch + Lomb to Return enVista IOLs to Market Following Voluntary Recallhttps://modernod.com/news/bausch-lomb-returning-envista-iols-to-market-following-voluntary-recall/2482752/Bausch + Lomb announced it has identified the event that led to its recent
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication
- Bausch + Lomb Recycles Over 625,000 Pounds of Eye Care Materialshttps://modernod.com/news/bausch-lomb-recycles-over-625000-pounds-of-eye-care-materials/2482745/Bausch + Lomb announced a sustainability milestone: its 'ONE by ONE' and 'Biotrue Eye Care' recycling programs have collectively diverted more than 103 million units, or 625,026 pounds, of used contact lenses and eye care materials fr
- MST Enters Strategic Partnership with Mani to Distribute Ophthalmic Surgical Blade Portfolio in the UShttps://modernod.com/news/microsurgical-technology-mst-enters-strategic-partnership-with-mani-to-distribute-ophthalmic-surgical-blade-portfolio-in-the-us/2482739/Microsurgical Technology (MST) announced a strategic partnership with Mani Inc. under which MST will serve as a distributor of Mani’s ophthalmic surgical blade portfolio in the United States. The deal is supported by the establishment of Mani Medical America, the US
- Biocon Biologics Secures Market Entry Date for Yesafili, Interchangeable Biosimilar to Eylea in the UShttps://modernod.com/news/biocon-biologics-secures-market-entry-date-for-yesafili-interchangeable-biosimilar-to-eylea-in-the-us/2482736/Biocon Biologics announced a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the United States. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is used to tre
- Oculis Completes Enrollment in Both DIAMOND Phase 3 Trials of OCS-01 in DMEhttps://modernod.com/news/oculis-completes-enrollment-in-both-diamond-phase-3-trials-of-ocs-01-in-dme/2482732/Oculis Holding said it has completed enrollment in both phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME. The trials are designed as pivotal registration studies to support global marketing applications including NDA submission and approval by t
- Tenpoint Therapeutics Submits NDA to FDA for Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/tenpoint-therapeutics-submits-nda-to-fda-for-brimochol-pf-for-the-treatment-of-presbyopia/2482730/Tenpoint Therapeutics announced that the company has submitted a new drug application (NDA) to the FDA for Brimochol PF for the treatment of presbyopia. BRIMOCHOL PF combines brimonidine and carbachol in a pupil-modulating eye dro
- Rayner Expands IOL Manufacturing Capacity to Meet Growing Demandhttps://modernod.com/news/rayner-expands-iol-manufacturing-capacity-to-meet-growing-demand/2482723/Rayner has completed a major expansion of its production facility in Worthing, UK, doubling its annual IOL manufacturing capacity to 4 million units, the company announced. Since opening its manufacturing pl
- Surrozen Discontinues Liver Program; Shifts Focus to Ophthalmologyhttps://modernod.com/news/surrozen-discontinues-liver-program-shifts-focus-to-ophthalmology/2482716/Surrozen announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs, including development of new treatment options for retinopathies. The company will use a $175-million private placement